| Name | NIK SMI1 |
| Description | NIK SMI1 is an effective and selective NF-κB inducing kinase (NIK) inhibitor. It also inhibits NIK-catalyzed hydrolysis of ATP to ADP (IC50: 0.23±0.17 nM). |
| In vitro | NIK SMI1 inhibits the expression of NIK SMI1 response element regulated firefly luciferase reporter gene in HEK293 cells (IC50: 34±6 nM). NIK SMI1 inhibits BAFF-induced B cell (mouse) survival in vitro with an IC50 of 373±64 nM. Consistent with expectations for a NIK inhibitor, NIK SMI1 is shown to inhibit nuclear translocation of p52 (RelB) (IC50=70 nM). |
| In vivo | The pharmacology of NIK SMI1 is examined in SD rat, CD-1 mouse, beagle, and cynomologous monkey with 20, 32, 18, and 7.8 mL/kg per min, respectively. The volume of distribution (Vd, L/kg) is 1.35, 1.58, 0.778, and 1.39, respectively. C57BL/6 mice are treated twice daily for 7 days with orally administered NIK SMI1 or with three injections of recombinant BAFF receptor fusion protein (Br3- mIgG2a) over the course of the 7-day experiment as a positive control . |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (273.69 mM), Sonication is recommended.
|
| Keywords | Nuclear factor-κB | NIK SMI 1 | Nuclear factor-kappaB | inhibit | NIK SMI1 | Inhibitor | NF-κB | NIK SMI-1 |
| Inhibitors Related | Sodium Houttuyfonate | Zingerone | Lidocaine | Diethylmaleate | Glucosamine | sodium lauroyl-α-hydroxyethyl sulfonate | Lidocaine hydrochloride | 5-Aminosalicylic Acid | Indole-3-carbinol | Diallyl disulfide | Caffeic Acid Phenethyl Ester | Sodium salicylate |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Antioxidant Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Transcription Factor-Targeted Compound Library |
United States
